Surmodics, Inc. Overview
Pro stress-test →Surmodics provides surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company became a wholly owned subsidiary of BCE Parent, LLC, an affiliate of GTCR LLC, on November 19, 2025.
Strategic Profile
Pro stress-test →The company operates through two segments: Medical Device (surface modification and drug-delivery coating technologies for coronary, peripheral, neurovascular and structural heart applications) and In Vitro Diagnostics (diagnostic immunoassay and molecular tests). Proprietary surface modification and drug-delivery coating capabilities are licensed to medical device manufacturers.
Competitive Landscape
Pro stress-test →Surmodics competes with larger diversified medical device companies (Medtronic, Boston Scientific) on specialized coating technologies and with diagnostics reagent suppliers. The company's differentiation lies in proprietary surface modification and drug-delivery coating capabilities that are licensed rather than sold directly, reducing direct competition exposure.
Industry Context
Surmodics, Inc. operates in Medical Device Coatings & In Vitro Diagnostics.
Key facts
Founded: 1987 · Headquarters: Eden Prairie, Minnesota · Employees: 389 · Revenue: $120M